ClinicalTrials.gg
CompletedNCT01033448Updated Oct 3, 2017Results posted

A Study of Extended Therapy of PEGASYS (Peginterferon Alfa-2a) in Combination With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C and Slow Response

A Phase 4 interventional study of COPEGUS and peginterferon alfa-2a [Pegasys] in Hepatitis C, Chronic, sponsored by Hoffmann-La Roche. Completed at 20 sites in Israel. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-10-03.

Sponsored by Hoffmann-La Roche · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
59
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 175 studies testing ribavirin in Hepatitis C, Chronic — none open to participants now, none under way, none of them phase 3. Ribavirin · Hepatitis C, Chronic.

Enrollment
119th of 174
59 · median 107
Started
2009
with 7 others
Phase 4
55 of 175
none open now
Registered
98th of 175
by date
Lead sponsor
28 of 175
Hoffmann-La Roche

Among the 175 studies testing ribavirin in Hepatitis C, Chronic, this one is the 119th largest by enrollment of the 174 interventional ones that give a count, is one of 8 that started in 2009, is one of 55 in phase 4, and was the 98th registered.

Hepatitis C, Chronic

950 studies on the registry are indexed under Hepatitis C, Chronic; 8 are open to participants now.

Browse Hepatitis C, Chronic studies →

Open to participants now

None of the 175 studies testing ribavirin in Hepatitis C, Chronic is open now. The open studies under Hepatitis C, Chronic, anywhere →

About ribavirin

Ribavirin: first FDA approval 1985 (VIRAZOLE), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 5 Hepatitis C, Chronic studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 175 studies testing ribavirin in Hepatitis C, Chronic as a file.
02

Study summary

This open-label, multi-center study will evaluate the safety and tolerability and the effect on viral activity of a combined PEGASYS and COPEGUS extended therapy in patients with chronic hepatitis C with genotype 1, 2 and 3. Patients who completed 48 weeks (genotype 1) or 24 weeks (genotype 2 and 3) of standard treatment with PEGASYS and COPEGUS and were identified as slow virological responders will be enrolled in this study in order to receive additional 24 weeks of treatment. PEGASYS 180 micrograms will be administered sc once weekly and COPEGUS will be administered as 800 mg, or 1000-1200 mg daily oral doses. The anticipated time on study treatment is 24 weeks. The target sample size is 50-150 patients.

03

Conditions studied

  • Hepatitis C, Chronic

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients >/= 18 years of age
  • Chronic , genotype 1, 2, 3
  • Compensated liver disease
  • Patients who completed 48 weeks or 24 weeks of standard treatment with PEGASYS and COPEGUS and were identified as slow virological responders

Exclusion criteria

Exclusion Criteria:

  • Decompensated liver disease
  • Signs or symptoms of hepatocellular carcinoma
  • Uncontrolled hypoglycaemia, hyperglycaemia and diabetes mellitus
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
59 participants (actual)

Study arms

  • Experimental
    Single arm

    Drug: COPEGUS · Drug: peginterferon alfa-2a [Pegasys]

Interventions

06

What researchers measure

Primary outcomes

  1. End of Treatment Response Rate at Week 72 in Genotype 1

    End of treatment response rate at Week 72 was reported for genotype 1.

    Time frame: Week 72

  2. End of Treatment Response in Genotype 2 and 3

    End of treatment response rate at Week 48 was reported for genotype 2 and 3.

    Time frame: Week 48

  3. Sustained Viral Response (SVR) Rates in CHC Genotype 1

    Sustained Viral Response, undetectable HCV-RNA 24 weeks after the end of treatment for genotype 1.

    Time frame: Week 96

  4. SVR Rates in Genotype 2 and 3.

    Sustained Viral Response, undetectable HCV-RNA 24 weeks after the end of treatment for genotype 2 and 3.

    Time frame: Week 72

Secondary outcomes

  1. Percentage of Participants With Adverse Event (AE)

    An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.

    Time frame: Week 96

07

Results

Posted Oct 3, 2017

Participant flow

Participants from Study NCT01429792 with genotype 1 Chronic Hepatitis C (CHC) and were 'Slow Responders' were eligible to enroll in this treatment extension study. Participants from Study NCT01429792 with genotype 2 and 3 CHC and were non-Rapid Virologic Response (RVR) were eligible to enroll in this treatment extension study.

Participant flow — Overall Study
MilestonePegylated Interferon (Peginterferon) Alfa-2a
Started59
Completed47
Not completed12
Withdrew: Withdrawal by subject4
Withdrew: Positive hcv-rna at week 481
Withdrew: Lost to follow-up3
Withdrew: Withdrew due to other reasons3
Withdrew: Unknown disposition1

Outcome measures

PrimaryEnd of Treatment Response Rate at Week 72 in Genotype 1

End of treatment response rate at Week 72 was reported for genotype 1.

Time frame:
Week 72
Reported as:
Number · Percentage of Participants
End of Treatment Response Rate at Week 72 in Genotype 1
Percentage of ParticipantsCHC Genotype 1
End of Treatment Response Rate at Week 72 in Genotype 168.2
PrimaryEnd of Treatment Response in Genotype 2 and 3

End of treatment response rate at Week 48 was reported for genotype 2 and 3.

Time frame:
Week 48
Reported as:
Number · Percentage of Participants
End of Treatment Response in Genotype 2 and 3
Percentage of ParticipantsCHC Genotype 2 and 3
End of Treatment Response in Genotype 2 and 366.7
PrimarySustained Viral Response (SVR) Rates in CHC Genotype 1

Sustained Viral Response, undetectable HCV-RNA 24 weeks after the end of treatment for genotype 1.

Time frame:
Week 96
Reported as:
Number · Percentage of participants
Sustained Viral Response (SVR) Rates in CHC Genotype 1
Percentage of participantsCHC Genotype 1
Sustained Viral Response (SVR) Rates in CHC Genotype 146.5 (31.2 to 62.3)
PrimarySVR Rates in Genotype 2 and 3.

Sustained Viral Response, undetectable HCV-RNA 24 weeks after the end of treatment for genotype 2 and 3.

Time frame:
Week 72
Reported as:
Number · Percentage of participants
SVR Rates in Genotype 2 and 3.
Percentage of participantsCHC Genotype 2 and 3
SVR Rates in Genotype 2 and 3.60.0 (32.3 to 83.7)
SecondaryPercentage of Participants With Adverse Event (AE)

An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.

Time frame:
Week 96
Reported as:
Number · Percentage of Participants
Percentage of Participants With Adverse Event (AE)
Percentage of ParticipantsPegylated Interferon (Peginterferon) Alfa2a
Percentage of Participants With Adverse Event (AE)40.7

Adverse events

Collected over Baseline to Week 96. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pegylated Interferon Alfa2a (Peginterferon)—5/59 (8.5%)14/59 (23.7%)
Most frequent serious events
Most frequent serious events
EventPegylated Interferon Alfa2a (Peginterferon)
PyrexiaGeneral disorders1/59
Anal AbscessInfections and infestations1/59
AnaesthesiaNervous system disorders1/59
Cerebrovascular accidentNervous system disorders1/59
Pregnancy of partnerSocial circumstances1/59
Most frequent other events
Most frequent other events
EventPegylated Interferon Alfa2a (Peginterferon)
AnaemiaBlood and lymphatic system disorders12/59
NeutropeniaBlood and lymphatic system disorders4/59

Baseline characteristics

All enrolled participants were included in the baseline population.

Age, Continuous
Age, Continuous(Years)Pegylated Interferon (Peginterferon) Alfa-2a
Mean47.9 ± 10.4
Sex: Female, Male
Sex: Female, Male(Participants)Pegylated Interferon (Peginterferon) Alfa-2a
Female34
Male25
08

Study locations

20 sites
  • Haemek Hospital; Gastroenterology
    Afula, 18101, Israel
  • Clalit City Ashdod MC; Liver Clinic
    Ashdod, 77444, Israel
  • Batyamon; Liver Unit
    Bat Yam, Israel
  • Soroka Medical Center; Gastroenterology
    Beer Sheva, 84105, Israel
  • Rambam Medical Center; Gastroenterology - Liver Unit
    Haifa, 31096, Israel
  • Bnei-Zion Medical Center; Gastroenterology
    Haifa, 33394, Israel
  • Carmel Hospital; Liver Unit
    Haifa, 34362, Israel
  • Wolfson Hospital; Gastroenterology Unit
    Holon, 58100, Israel
  • Hadassah Hospital; Liver Unit
    Jerusalem, 91120, Israel
  • Clalit Strauss MC
    Jerusalem, 95146, Israel
  • Meir Medical Center; Gastroenterology
    Kfar Saba, 44281, Israel
  • Naharyia / Western Galilee MC; Gastro Unit
    Nahariya, 22100, Israel
  • Holy Family Medical Center; Gastroenterology
    Nazareth, Israel
  • Rabin Medical Center; Gastroenterology - Liver Unit
    Petach Tikva, 49100, Israel
  • Kaplan Medical Center; Gastroenterology Unit
    Rehovot, 76100, Israel
  • Clalit Pinsker Rishon; Liver Clinic
    Rishon Lezion, 75299, Israel
  • Rebecca Sieff Medical Center; Liver Unit
    Safed, 13110, Israel
  • Maccabi Health Services MC
    Tel Aviv, 67891, Israel
  • Poria Hospital; Gastroenterology
    Tiberias, Israel
  • Assaf Harofeh; Gastroenterology
    Zerifin, 6093000, Israel
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2009, a primary completion of Jun 2013 and a completion of Jun 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2017, 4 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 15, 2009
First posted
Dec 16, 2009
Start
Dec 2009
Primary completionActual
Jun 2013
CompletionActual
Jun 2013
Results first posted
Oct 3, 2017
Last update
Oct 3, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 3, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01033448
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Dec 16, 2009
Start date
Dec 2009
Primary completion
Jun 2013
Completion
Jun 2013
Results posted
Oct 3, 2017
Last update
Oct 3, 2017

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ribavirin · Peginterferon alfa-2a

Start the discussion